537 related articles for article (PubMed ID: 35514989)
1. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
Front Immunol; 2022; 13():874108. PubMed ID: 35514989
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.
Chebani R; Lombart F; Chaby G; Dadban A; Debarbieux S; Viguier MA; Ingen-Housz-Oro S; Pham-Ledard A; Bedane CR; Picard-Dahan C; Berthin C; Dereure O; Konstantinou MP; Castel M; Jouen F; Joly P; Seta V; Duvert-Lehembre S; Le Roux C; Quereux G; Sassolas B; Brenaut E; Sin C; Richard MA; Bérard F; Giusti D; Belmondo T; Gille T; Caux F; Prost-Squarcioni C; Grootenboer-Mignot S; Alexandre M;
Br J Dermatol; 2024 Jan; 190(2):258-265. PubMed ID: 37792727
[TBL] [Abstract][Full Text] [Related]
4. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
[TBL] [Abstract][Full Text] [Related]
5. IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis.
Christophoridis S; Büdinger L; Borradori L; Hunziker T; Merk HF; Hertl M
Br J Dermatol; 2000 Aug; 143(2):349-55. PubMed ID: 10951144
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
7. A Case of Anti-BP180-type Mucous Membrane Pemphigoid with IgG and IgA Autoantibodies Showing Distinct Reactivities.
Minakawa S; Matsuzaki Y; Hashimoto T; Ishii N; Nishie W; Nakazawa M; Sawamura D
Acta Dermatovenerol Croat; 2022 Jul; 30(1):54-56. PubMed ID: 36153720
[TBL] [Abstract][Full Text] [Related]
8. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results.
Kamata A; Kurihara Y; Funakoshi T; Takahashi H; Kuroda K; Hachiya T; Amagai M; Yamagami J
Br J Dermatol; 2020 May; 182(5):1221-1227. PubMed ID: 31330562
[TBL] [Abstract][Full Text] [Related]
9. Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis.
Yayli S; Pelivani N; Beltraminelli H; Wirthmüller U; Beleznay Z; Horn M; Borradori L
Br J Dermatol; 2011 Nov; 165(5):1133-7. PubMed ID: 21711326
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid.
Vassallo C; Somenzi A; De Amici M; Barruscotti S; Brazzelli V
Dermatol Ther; 2022 Dec; 35(12):e15946. PubMed ID: 36259470
[TBL] [Abstract][Full Text] [Related]
11. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases.
van Beek N; Schulze FS; Zillikens D; Schmidt E
Expert Rev Clin Immunol; 2016; 12(3):267-77. PubMed ID: 26588556
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin E and bullous pemphigoid.
Cozzani E; Gasparini G; Di Zenzo G; Parodi A
Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
[TBL] [Abstract][Full Text] [Related]
13. Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.
Seyed Jafari SM; Gadaldi K; Feldmeyer L; Yawalkar N; Borradori L; Schlapbach C
Front Immunol; 2019; 10():1919. PubMed ID: 31474990
[TBL] [Abstract][Full Text] [Related]
14. Fc-binding proteins enhance autoantibody-induced BP180 depletion in pemphigoid.
Iwata H; Kamaguchi M; Ujiie H; Ujiie I; Natsuga K; Nishie W; Shimizu H
J Pathol; 2019 Mar; 247(3):371-380. PubMed ID: 30426510
[TBL] [Abstract][Full Text] [Related]
15. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.
Iwata Y; Komura K; Kodera M; Usuda T; Yokoyama Y; Hara T; Muroi E; Ogawa F; Takenaka M; Sato S
Arch Dermatol; 2008 Jan; 144(1):41-8. PubMed ID: 18209167
[TBL] [Abstract][Full Text] [Related]
16. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
17. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.
Fairley JA; Fu CL; Giudice GJ
J Invest Dermatol; 2005 Sep; 125(3):467-72. PubMed ID: 16117787
[TBL] [Abstract][Full Text] [Related]
18. Research progress of omalizumab in the treatment of bullous pemphigoid.
Ling X; Shou X; Lou Y; Ling J; Zhang M; Yu T; Gu W
J Dermatol; 2023 May; 50(5):575-587. PubMed ID: 36971190
[TBL] [Abstract][Full Text] [Related]
19. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.
James T; Salman S; Stevenson B; Bundell C; Kelly G; Nolan D; John M
Clin Immunol; 2019 Jan; 198():54-56. PubMed ID: 30557620
[TBL] [Abstract][Full Text] [Related]
20. Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity.
Emtenani S; Linnemann BE; Recke A; von Georg A; Goletz S; Schmidt E; van Beek N
J Dermatol Sci; 2024 May; 114(2):64-70. PubMed ID: 38582700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
